- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00001317
A Phase IV Study of Recombinant Human Gamma Interferon in Patients With Chronic Granulomatous Diseases of Childhood
In a recent double-blinded, placebo-controlled multi-center international study, subcutaneous injections of interferon-gamma administered three times weekly reduced the frequency of serious infections in patients with chronic granulomatous disease. Patients receiving interferon-gamma had fewer hospital stays, shorter in length, than the placebo group. Children less than 10 years of age benefitted most from treatment and had fewer side effects.
Based on these data, the FDA licensed interferon-gamma for prophylaxis in CGD patients. We wish to monitor our patients who participated in the original study for possible long-term side effects. Any new patients referred to us who are either on interferon-gamma or considered to be candidates for interferon-gamma will be considered for this protocol. In addition, our patients who were originally accepted under Genentech's compassionate plea protocol will also be monitored under this new protocol. The patients will be evaluated every six months, with blood work and interim medical histories taken.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In a recent double-blinded, placebo-controlled multi-center international study, subcutaneous injections of interferon-gamma administered three times weekly reduced the frequency of serious infections in patients with chronic granulomatous disease. Patients receiving interferon-gamma had fewer hospital stays, shorter in length, than the placebo group. Children less than 10 years of age benefitted most from treatment and had fewer side effects.
Based on these data, the FDA licensed interferon-gamma for prophylaxis in CGD patients. We wish to monitor our patients who participated in the original study for possible long-term side effects. Any new patients referred to us who are either on interferon-gamma or considered to be candidates for interferon-gamma will be considered for this protocol. In addition, our patients who were originally accepted under Genentech's compassionate plea protocol will also be monitored under this new protocol. The patients will be evaluated every six months, with blood work and interim medical histories taken.
Study Type
Enrollment
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institute of Allergy and Infectious Diseases (NIAID)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
The diagnosis of chronic granulomatous disease as indicated by an unusual pattern of infection in the patient or one pedigree relation, confirmed by both of the following tests:
Abnormal neutrophil NBT slide test (following PMA stimulation) and neutrophil superoxide anion production less than or equal to 20 percent normal.
Preserved renal function (creatinine less than or equal to 2.0 mg/100 mL; less than or equal to 2+ proteinuria).
Preserved hepatic function (bilirubin less than or equal to 1.5 mg/100 mL; prothrombin time less than or equal to 1.3 x control).
Preserved hematologic function (WBC greater than or equal to 3000/mm3; granulocytes greater than 1500/mm3; platelets greater than or equal to 100,000/mm3).
A minimum life expectancy of three months.
Patients seropositive for Hepatitis B surface antigen may be entered but serum specimens for rIFN-y antibody should not be collected.
Patients must not be pregnant or lactating.
Patients of childbearing potential may be entered if using effective contraception.
Full recovery from previous serious infections requiring hospitalization and parenteral antibiotic therapy. At least two weeks must elapse following the cessation of parenteral antibiotic therapy before study admission.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
Publications and helpful links
General Publications
- Ross JP, Holland SM, Gill VJ, DeCarlo ES, Gallin JI. Severe Burkholderia (Pseudomonas) gladioli infection in chronic granulomatous disease: report of two successfully treated cases. Clin Infect Dis. 1995 Nov;21(5):1291-3. doi: 10.1093/clinids/21.5.1291.
- Gallin JI, Farber JM, Holland SM, Nutman TB. Interferon-gamma in the management of infectious diseases. Ann Intern Med. 1995 Aug 1;123(3):216-24. doi: 10.7326/0003-4819-123-3-199508010-00009.
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Hematologic Diseases
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Leukocyte Disorders
- Phagocyte Bactericidal Dysfunction
- Granuloma
- Granulomatous Disease, Chronic
- Anti-Infective Agents
- Antiviral Agents
- Antineoplastic Agents
- Interferons
- Interferon-gamma
Other Study ID Numbers
- 920186
- 92-I-0186
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Granulomatous Disease
-
National Institute of Allergy and Infectious Diseases...Enrolling by invitationChronic Granulomatous Disease (CGD) | X-Linked Chronic Granulomatous DiseaseUnited States
-
University of California, Los AngelesNational Heart, Lung, and Blood Institute (NHLBI); Boston Children's Hospital; California Institute for Regenerative Medicine (CIRM) and other collaboratorsRecruitingGranulomatous Disease, Chronic, X-linkedUnited States
-
National Institute of Allergy and Infectious Diseases...Active, not recruitingChronic Granulomatous Disease TransplantUnited States
-
GenethonActive, not recruitingX-Linked Chronic Granulomatous DiseaseFrance
-
Children's Hospital of Fudan UniversityRecruitingBCG | Vitamin D3 | Chronic-granulomatous DiseaseChina
-
Great Ormond Street Hospital for Children NHS Foundation...WithdrawnGranulomatous Disease, Chronic, X-linked, VariantUnited Kingdom
-
National Institute of Allergy and Infectious Diseases...RecruitingChronic Granulomatous Disease-associated ColitisUnited States
-
GenethonActive, not recruitingX-Linked Chronic Granulomatous DiseaseUnited Kingdom
-
National Institute of Allergy and Infectious Diseases...Rare Diseases Clinical Research Network; Primary Immune Deficiency Treatment...Enrolling by invitationGranulomatous Disease, ChronicUnited States, Canada
-
Hubert Serve, Prof., MDUnknown
Clinical Trials on interferon-gamma
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Horizon Pharma USA, Inc.TerminatedMyxoid Liposarcoma | Synovial Sarcoma | Round Cell LiposarcomaUnited States
-
SPP Pharmaclon Ltd.RecruitingPulmonary TuberculosisRussian Federation
-
SPP Pharmaclon Ltd.CompletedCommunity-acquired PneumoniaRussian Federation
-
SPP Pharmaclon Ltd.RecruitingRespiratory TuberculosisRussian Federation
-
SPP Pharmaclon Ltd.North-Western State Medical University named after I.I.MechnikovCompletedRNA Virus Infections | Lentivirus Infections | Tuberculosis, Pulmonary | Human Immunodeficiency Virus | HIV Coinfection | Aids/Hiv ProblemRussian Federation
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)CompletedTuberculosis | AIDS-related ComplexUnited States, South Africa
-
SPP Pharmaclon Ltd.CompletedCOVID-19 Respiratory Infection | Viral PneumoniaRussian Federation
-
Nantes University HospitalActive, not recruiting
-
SPP Pharmaclon Ltd.Completed
-
SPP Pharmaclon Ltd.CompletedHuman Papillomavirus Infection | Anogenital WartsRussian Federation